Turning Point Therapeutics Inc (TP therapeutics), a subsidiary of Bristol-Myers Squibb Co, is a biopharmaceutical company. It designs and develops clinical stage small molecule, targeted oncology therapies to address key limitations of existing lung cancer therapies. The company's pipeline products include Repotrectinib, macrocyclic tyrosine kinase inhibitor, TPX-0022, multi-targeted kinase inhibitor, TPX-0046, a multi-targeted orally bioavailable TKI, TPX - 013 and ALK inhibitor. TP therapeutics provides clinical trial activities such as TRIDENT-1 and compassionate use programs. The company’s macrocyclic platform addresses the issues of emerging treatment resistance and toxicities that limit duration of treatment. It operates in the US and Switzerland. TP Therapeutics is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
Suite 200, 10628 Science Center Drive, San Diego, California, 92121
Website
www.tptherapeutics.com
Telephone
1 858 9265251
No of Employees
267
Industry
Pharmaceuticals and Healthcare
Turning Point Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Elzovantinib | Clinical Trials |
| Repotrectinib | Investigator Sponsored Research |
| TPX-0022 | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Turning Point Therapeutics Inc | Y-mAbs Therapeutics Inc | Protagonist Therapeutics Inc | BioAtla Inc | Biopact Cellular Transport Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | San Diego | New York | Newark | San Diego | Austin |
| State/Province | California | New York | California | California | Texas |
| No. of Employees | 267 | 147 | 111 | 66 | - |
| Entity Type | Private | Public | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Athena Countouriotis | Chief Executive Officer; President | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward